Reading BIIB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIIB free→Reading BIIB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIIB free→QuarterlyIQ Insights · BIIB
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(8.6) + peer(0.2*8.0) + term(0.0) → 4.6% (capped ±15.0)
in 47 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 1 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On April 29, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the first quarter of 2026 by approximately $0.19 per share. Acquired in-process research and development, upfront and milesto…
Results of Operations and Financial Condition. On February 6, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the fourth quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $222 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the fourth quarter 2025 by approximately $1.26 per share. During the first quarter of 2025 we began presenting acquired in-…
Results of Operations and Financial Condition. On October 30, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the third quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $2 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the third quarter 2025 by approximately ($0.01) per share. During the first quarter of 2025 we began presenting acquired in-pr…
Results of Operations and Financial Condition. On July 31, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $46 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the second quarter 2025 by approximately ($0.26) per share. During the first quarter of 2025 we began presenting acquired in…
Results of Operations and Financial Condition. On May 1, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On February 12, 2025, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On October 30, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On August 1, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On April 24, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On February 13, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On November 8, 2023, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition. On July 25, 2023, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to